Is Hydroxychloroquine Safe During Pregnancy? Observations from Penn Medicine
Davidson, L.; Canelon, S.; Boland, M. R.
Show abstract
A novel strain of coronavirus appeared in December 2019. Over the next few months, this novel coronavirus spread throughout the world, being declared a pandemic by the World Health Organization on March 11, 2020. As of this writing (March 28, 2020) over one hundred thousand individuals in the United States of America were confirmed cases. One way of treating the associated disease, COVID-19, is to reuse existing FDA-approved medications. One medication that has shown promise is hydroxychloroquine (HCQ). However, the utility and safety of HCQ among pregnant COVID-19 patients remains a concern.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Systematic analysis of electronic health records identifies drugs reducing risk of COVID-19 hospitalization and severity 88%
- NBI-921352, a First-in-Class, Na V 1.6 Selective, Sodium Channel Inhibitor That Prevents Seizures in Scn8a Gain-of- Function Mice, and Wild-Type Mice and Rats 87%
- Concentration-dependent mortality of chloroquine in overdose 86%
Similar papers in this journal
- AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial 88%
- Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study 87%
- Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial 87%
Similar papers in this journal
Similar papers in this journal
- The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy 86%
- More than efficacy revealed by single-cell analysis of antiviral therapeutics 85%
- An acyclic nucleoside phosphonate effectively blocks the egress of the malaria parasite by inhibiting the synthesis of cyclic GMP. 84%
Similar papers in this journal
- Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia 89%
- Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ) 89%
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.